Skip to main content
An official website of the United States government

Resources for News Media

The NCI press office is the central news contact for all members of the media. The office can assist you in arranging interviews with NCI researchers and in providing accurate and timely cancer research news and information.

For information about NCI's history and current activities, see NCI Overview and Budget and Appropriations.

Connect with Us

Our office hours are Monday through Friday, 9 a.m. to 5 p.m. ET.

Phone: 240-760-6600
Social Media:
NCI's YouTube Channel

Building 31, Room 10A25
31 Center Drive MSC 2580
Bethesda, MD 20892-2580

Recent Interviews from Scientists at NCI

From left to right, Monica M. Bertagnolli, M.D., Jeff Shilling, Douglas R. Lowy, M.D., Alice Chen Grady, M.D., Katrina A.B. Goddard, Ph.D., Wayne Lawrence, Dr.P.H., M.P.H, Philip E. Castle, Ph.D., M.P.H., and Shobha Srinivasan, Ph.D.

From left to right, Monica M. Bertagnolli, M.D., Jeff Shilling, Douglas R. Lowy, M.D., Alice Chen Grady, M.D., Katrina A.B. Goddard, Ph.D., Wayne Lawrence, Dr.P.H., M.P.H, Philip E. Castle, Ph.D., M.P.H., and Shobha Srinivasan, Ph.D.

  • Experts Discuss Grail Blood Test For Cancer, Concerns Over Quality, Overtesting

    August 11, 2023 | KFF Health News
    An article published by KFF Health News and reprinted in multiple outlets, including the Philadelphia Inquirer, looked at “multi-cancer early-detection (MCED) tests, which analyze DNA fragments in the blood for abnormalities associated with cancer.” Among the experts interviewed was the National Cancer Institute Cancer Prevention Director Philip Castle.

  • NCI’s Shobha Srinivasan Discusses Agency’s Goal Of Improving Cancer Results For People In Poverty

    August 7, 2023 | Federal News Network
    Federal Drive with Tom Temin interviewed NCI Senior Advisor for Health Disparities Shobha Srinivasan about the details of the organization’s new grants. “Poverty often means less access to good health care, and therefore worse outcomes than those of the wealthy.” Now, the NCI “has awarded $50 million in grants to establish five new organizations devoted to cancer prevention and care.”

  • Dog cancer research advances pursuit of drugs for humans and canines

    June 20, 2023 | The Washington Post
    Compelling genetic data, increased funding and growing collaborations in the past decade are pushing forward development of cancer drugs for both canines and humans

  • Involving All of Society to End Cancer as We Know It

    June 10, 2023 | The ASCO Post
    This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months later, on December 14, 2002, Dr. Bertgnolli became the first publicly known Director of the NCI to be diagnosed with cancer and to undergo treatment while heading the agency.

  • NCI Program Explores Best Practices for Enrolling Underserved Groups to Precision Oncology Trials

    June 6, 2023 | Precision Medicine Online
    CHICAGO – A National Cancer Institute-funded study exploring strategies for diversifying clinical trials found community engagement, study navigators, and telemedicine showed promise in enrolling patients traditionally left out of research, but efforts to screen for and enlist study participants harboring specific biomarkers of interest weren't as successful.

  • Action Needed to Hit 'Moonshot' Goal of Halving Cancer Deaths by Mid-Century

    April 17, 2023 | HealthDay
    The United States will fall short of its Cancer Moonshot goal of cutting cancer deaths by at least half over the next 25 years unless more action is taken, a new U.S. National Cancer Institute analysis concludes.

  • Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

    April 14, 2023 | CURE
    The National Cancer Institute (NCI) launched the phase 3 Pragmatica-Lung Study (S2302) clinical trial evaluating Cyramza (ramucirumab) plus Keytruda (pembrolizumab) for patients with stage 3 or recurrent non-small cell lung cancer, according to a press release from the agency.

  • How the cloud is letting the National Cancer Institute take the IT burden off its mission areas

    March 31, 2023 | Federal News Network
    The National Cancer Institute is keeping its IT modernization strategy pretty simple. There is cloud one and there is cloud two. All new development will reside in one of those two instances.

  • The Cancer Moonshot Enters a New Phase

    January 25, 2023 | IEEE Pulse
    Moonshot-supported research has made progress in lowering cancer mortality rates, and this new initiative prioritizes diversity in research with a goal of ending cancer as we know it

Trending Topics

  • Cancer Moonshot Scholars

    The Cancer Moonshot Scholars program is designed to advance cancer science while also diversifying the pool of researchers and the approaches to cancer research that NCI funds. The program seeks to enhance the number of applications submitted by Early Stage Investigators from diverse backgrounds, including those from groups identified as underrepresented) in the biomedical, clinical, behavioral, and social sciences research workforce.

  • National Cancer Plan - Join Us

    People across the country and worldwide are counting on us to end cancer as we know it. Research alone will not accomplish this. To succeed, we must work together to develop strategies, share knowledge, and accelerate progress. The National Cancer Plan provides a comprehensive framework for this meaningful collaboration and unites us in acting on the vision President Biden and First Lady Biden set out in the Cancer Moonshot℠ to end cancer as we know it.

  • Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

    Article on ScienceDirect - Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility; Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry.

  • White House Fact Sheet: On One Year Anniversary of Reignited Cancer Moonshot, Biden-⁠Harris Administration Announces New Actions to End Cancer as We Know It

    One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.

  • HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments

    HER2 is a gene that has been linked to breast cancer growth. Learn about the development of trastuzumab, a monoclonal antibody that blocks the HER2 protein, and other treatments that have improved survival for women with HER2-positive breast cancer.

  • Breast Cancer—Patient Version

    Breast cancer is the second most common cancer in women after skin cancer. Mammograms can detect breast cancer early, possibly before it has spread. Start here to find information on breast cancer treatment, causes and prevention, screening, research, and statistics.

  • Uterine Cancer—Patient Version

    Uterine cancers can be of two types: endometrial cancer (common) and uterine sarcoma (rare). Endometrial cancer can often be cured. Uterine sarcoma is often more aggressive and harder to treat. Start here to find information on uterine cancer treatment, causes and prevention, screening, research, and statistics.

  • Cancer Treatment Vaccines

    Cancer treatment vaccines treat cancer by strengthening the body’s natural defenses against the cancer. This page covers how cancer treatment vaccines work against cancer, cancers that are treated with them, and the side effects they may cause.

  • Cancer death rates among Black people declined over time, but remain higher than other racial and ethnic groups

    From 1999—2019, US rates of cancer death fell among Black people. Yet, in 2019, their rates remained higher than those of other racial and ethnic groups.

  • NCI COVID-19 in Cancer Patients Study (NCCAPS)

    The NCI COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. The knowledge gained from this study will help doctors better manage treatment for people with cancer and COVID-19 in the future.

Multimedia from NCI

50 Years of Cancer Treatment and Diagnostics

Clinical trials, innovation in research, and technology have improved cancer treatment and diagnostics in public health. Listen to Healthcast’s National Cancer Act podcast series to learn more.


Recent News Releases